Literature DB >> 22089469

The ClASsification for Psoriatic ARthritis (CASPAR) criteria--a retrospective feasibility, sensitivity, and specificity study.

William Tillett1, Luisa Costa, Deepak Jadon, Dinny Wallis, Charlotte Cavill, Jessica McHugh, Eleanor Korendowych, Neil McHugh.   

Abstract

OBJECTIVE: To evaluate the sensitivity, specificity, and feasibility of the ClASsification criteria for Psoriatic ARthritis (CASPAR) to retrospectively classify an existing research cohort.
METHODS: In total, 480 patient records were reviewed from the Royal National Hospital for Rheumatic Diseases Psoriatic Arthritis (PsA) cohort and for 100 consecutive controls with inflammatory arthritis from a general rheumatology clinic. The CASPAR score was modified for retrospective use; both "inflammation" and "current psoriasis" were recorded as present if they had ever been confirmed in the rheumatology clinic. Sensitivity and specificity of the CASPAR criteria were compared with expert clinical diagnosis.
RESULTS: A total of 480 database records were identified. Nine sets of records had been lost or destroyed. The diagnoses had changed in 15 cases, which were transferred to the control arm, leaving 456 patients with an expert diagnosis of PsA. Of 115 controls, 96 had rheumatoid arthritis, 5 osteoarthritis, 3 reactive arthritis, 3 seronegative arthritis, 3 undifferentiated arthralgia, 2 ankylosing spondylitis, 1 spondyloarthritis, and 2 systemic sclerosis. Sensitivity (99.7%) and specificity (99.1%) were both high and equivalent to previous reports. Sensitivity remained high even after inclusion of 7 PsA patients with insufficient data to complete the CASPAR assessment (sensitivity 98.2%, specificity 99.1%). The criteria were found to be easy and practical to apply to case records.
CONCLUSION: Our study demonstrates that the feasibility, specificity, and sensitivity of the CASPAR are maintained when adapted for retrospective use to classify an established research cohort.

Entities:  

Mesh:

Year:  2011        PMID: 22089469     DOI: 10.3899/jrheum.110845

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  40 in total

1.  Metabolic syndrome and its relationship with the achievement of minimal disease activity state in psoriatic arthritis patients: an observational study.

Authors:  Luisa Costa; Francesco Caso; Roberta Ramonda; Antonio Del Puente; Luca Cantarini; Md Abud Darda; Paolo Caso; Mariagrazia Lorenzin; Ugo Fiocco; Leonardo Punzi; Raffaele Scarpa
Journal:  Immunol Res       Date:  2015-02       Impact factor: 2.829

Review 2.  Psoriatic arthritis: phenotypic variance and nosology.

Authors:  Lihi Eder; Dafna D Gladman
Journal:  Curr Rheumatol Rep       Date:  2013-03       Impact factor: 4.592

Review 3.  Psoriatic arthritis and psoriasis: differential diagnosis.

Authors:  Maddalena Napolitano; Francesco Caso; Raffaele Scarpa; Matteo Megna; Angela Patrì; Nicola Balato; Luisa Costa
Journal:  Clin Rheumatol       Date:  2016-05-07       Impact factor: 2.980

Review 4.  Metabolic syndrome in psoriatic arthritis: the interplay with cutaneous involvement. Evidences from literature and a recent cross-sectional study.

Authors:  Francesco Caso; Antonio Del Puente; Francesca Oliviero; Rosario Peluso; Nicolò Girolimetto; Paolo Bottiglieri; Francesca Foglia; Carolina Benigno; Marco Tasso; Leonardo Punzi; Raffaele Scarpa; Luisa Costa
Journal:  Clin Rheumatol       Date:  2018-01-08       Impact factor: 2.980

Review 5.  Apremilast in the treatment of psoriatic arthritis: a perspective review.

Authors:  Michael Reed; David Crosbie
Journal:  Ther Adv Musculoskelet Dis       Date:  2017-01-20       Impact factor: 5.346

6.  Comparative microscopic analysis of nail clippings from patients with cutaneous psoriasis and psoriatic arthritis.

Authors:  Gabriela Poglia Fonseca; Betina Werner; Gabriela Seidel; Henrique Luiz Staub
Journal:  An Bras Dermatol       Date:  2017 Jan-Feb       Impact factor: 1.896

Review 7.  Clinical Features of Psoriatic Arthritis: a Comprehensive Review of Unmet Clinical Needs.

Authors:  Angela McArdle; Stephen Pennington; Oliver FitzGerald
Journal:  Clin Rev Allergy Immunol       Date:  2018-12       Impact factor: 8.667

8.  Minimal disease activity in patients with psoriatic arthritis treated with ustekinumab: results from a 24-week real-world study.

Authors:  Maddalena Napolitano; Luisa Costa; Francesco Caso; Matteo Megna; Raffaele Scarpa; Nicola Balato; Fabio Ayala; Anna Balato
Journal:  Clin Rheumatol       Date:  2017-05-31       Impact factor: 2.980

9.  Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial.

Authors:  Ana C Medeiros-Ribeiro; Nadia E Aikawa; Carla G S Saad; Emily F N Yuki; Tatiana Pedrosa; Solange R G Fusco; Priscila T Rojo; Rosa M R Pereira; Samuel K Shinjo; Danieli C O Andrade; Percival D Sampaio-Barros; Carolina T Ribeiro; Giordano B H Deveza; Victor A O Martins; Clovis A Silva; Marta H Lopes; Alberto J S Duarte; Leila Antonangelo; Ester C Sabino; Esper G Kallas; Sandra G Pasoto; Eloisa Bonfa
Journal:  Nat Med       Date:  2021-07-30       Impact factor: 53.440

Review 10.  Pharmacological treatment of spondyloarthritis: exploring the effectiveness of nonsteroidal anti-inflammatory drugs, traditional disease-modifying antirheumatic drugs and biological therapies.

Authors:  Francesco Caso; Luisa Costa; Antonio Del Puente; Matteo Nicola Dario Di Minno; Gelsy Lupoli; Raffaele Scarpa; Rosario Peluso
Journal:  Ther Adv Chronic Dis       Date:  2015-11       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.